EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery of novel FGF trap small molecules endowed with anti-myeloma activity

Sara Taranto, Riccardo Castelli, Giuseppe Marseglia, Laura Scalvini, Federica Vacondio, Alessandra Gianoncelli, Giovanni Ribaudo, Jessica Faletti, Giorgia Gazzaroli, Edoardo Rocca, Roberto Ronca, Marco Rusnati und 6 weitere

Pharmacological Research · 2024

DOI: 10.1016/j.phrs.2024.107291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Research, 2024. Verfasst von Sara Taranto und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Clinical Trial Center, Translational Research and Phase I …. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Agents, Receptors, Fibroblast Growth Factor, Fibroblast Growth Factors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast growth factors (FGFs) act as proangiogenic and mitogenic cytokines in several cancers, including multiple myeloma (MM). Indeed, corrupted FGF autocrine and paracrine secretion induces an aberrant activation of the FGF receptor (FGFR) signaling sustaining cancer cell spreading and resistance to pharmacological treatments. Thus, FGF traps may represent a promising anti-cancer strategy to hamper the ligand-dependent activation of the FGF/FGFR system. We previously identified NSC12 as the first orally available small molecule FGF trap able to inhibit the growth and progression of several FGF-dependent tumor models. NSC12 is a pregnenolone derivative carrying a 1,1-bis-trifluoromethyl-1,3-propanediol chain in position 17 of the steroid nucleus. Investigation of structure-activity relationships (SARs) provided more potent and specific NSC12 steroid derivatives and highlighted that the C17-side chain is pivotal for the FGF trap activity. Here, a scaffold hopping approach allowed to obtain two FGF trap compounds (22 and 57) devoid of the steroid nucleus and able to efficiently bind FGF2 and to inhibit FGFR activation in MM cells. Accordingly, these compounds exert a potent anti-tumor activity on MM cell lines both in vitro and in vivo and on MM patient-derived primary cells, strongly affecting the survival of both proteasome-inhibitor sensitive and resistant MM cells. These results propose a new therapeutic option for relapsed/refractory MM patients and set the bases for the development of novel FGF traps prone to chemical diversification to be used in the clinic for the treatment of those tumors in which the FGF/FGFR system plays a pivotal role, including MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic AgentsReceptors, Fibroblast Growth FactorFibroblast Growth FactorsHumansAnimalsCell Line, TumorStructure-Activity RelationshipDrug DiscoveryMiceFibroblast Growth Factor 2

Stichwörter der Autor:innen

FGF trapFGFRNSC12multiple myeloma

Substanzen

Antineoplastic AgentsReceptors, Fibroblast Growth FactorFibroblast Growth FactorsFibroblast Growth Factor 2

Autor:innen und Institutionen

  • Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Clinical Trial Center, Translational Research and Phase I Unit, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Department of Food and Drug, University of Parma, Parma, Italy.
  • Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
  • Clinical Trial Center, Translational Research and Phase I Unit, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. Electronic address: arianna.giacomini@unibs.it.
  • Department of Food and Drug, University of Parma, Parma, Italy. Electronic address: silvia.rivara@unipr.it.

Zitieren

APA

Taranto, S., Castelli, R., Marseglia, G., Scalvini, L., Vacondio, F., Gianoncelli, A., Ribaudo, G., Faletti, J., Gazzaroli, G., Rocca, E., Ronca, R., Rusnati, M., Sacco, A., Roccaro, A. M., Presta, M., Mor, M., Giacomini, A., & Rivara, S. (2024). Discovery of novel FGF trap small molecules endowed with anti-myeloma activity. Pharmacological Research. https://doi.org/10.1016/j.phrs.2024.107291

Vancouver

Taranto S, Castelli R, Marseglia G, Scalvini L, Vacondio F, Gianoncelli A, et al. Discovery of novel FGF trap small molecules endowed with anti-myeloma activity. Pharmacological Research. 2024. doi:10.1016/j.phrs.2024.107291

BibTeX
@article{Taranto2024,
  author = {Taranto, Sara and Castelli, Riccardo and Marseglia, Giuseppe and Scalvini, Laura and Vacondio, Federica and Gianoncelli, Alessandra and Ribaudo, Giovanni and Faletti, Jessica and Gazzaroli, Giorgia and Rocca, Edoardo and Ronca, Roberto and Rusnati, Marco and Sacco, Antonio and Roccaro, Aldo Maria and Presta, Marco and Mor, Marco and Giacomini, Arianna and Rivara, Silvia},
  title = {Discovery of novel FGF trap small molecules endowed with anti-myeloma activity},
  journal = {Pharmacological Research},
  year = {2024},
  doi = {10.1016/j.phrs.2024.107291}
}
Kostenlos starten →